We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Events

09 Feb 2026 - 12 Feb 2026
22 Feb 2026 - 24 Feb 2026

Ultrasound Device Offers Non-Invasive Treatment for Kidney Stones

By HospiMedica International staff writers
Posted on 26 Jan 2026

The U. More...

S. Food and Drug Administration has granted 510(k) clearance to SonoMotion’s Break Wave lithotripsy device, which fragments stones non-invasively with focused ultrasound and requires no anesthesia. Break Wave uses low‑pressure focused ultrasound under real‑time ultrasound guidance to create standing stress waves inside the stone, fragmenting calculi in the kidney or ureter while patients remain fully awake. 

"Break Wave provides a new option for the safe and effective treatment of kidney stones that can be performed in nearly any healthcare setting and does not require a ureteral stent," said Helena Chang, MD, Kaiser Permanente. "Patients with symptomatic obstructing ureteral stones can move immediately to treatment, saving weeks of pain and discomfort trying to pass a stone. Additionally, patients with asymptomatic kidney stones have an option to treat stones before they cause a painful event."

The 510(k) clearance advances SonoMotion’s anesthesia-free platform, which also includes Stone Clear, a device designed to aid removal of residual fragments following lithotripsy and cleared through the FDA’s de novo pathway in October 2024. Together, the two devices offer a noninvasive, anesthesia-free treatment approach, with Break Wave fragmenting kidney stones and Stone Clear facilitating post-lithotripsy fragment clearance.

"Receiving FDA clearance is a pivotal milestone for our company and, more importantly, for patients seeking better options for kidney stone treatment," said Oren Levy, PhD, Co-Founder and Chief Executive Officer of SonoMotion. "This 510(k) clearance represents a significant step toward commercialization, and we look forward to scaling manufacturing and making our non-invasive, anesthesia-free solutions available to patients and providers across the urology community. We are deeply grateful to the patients who participated in our studies, as well as the support from clinicians, investors, NASA, and the NIH."

Related Links
SonoMotion


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.